New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 5, 2013
10:00 EDTVTNC, BT, MAT, JNPR, NAUH, WMC, MFA, RIGL, TEX, KMB, COR, FFIV, EVROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CoreSite Realty (COR) downgraded to Sell from Hold at Cantor... Evercore Partners (EVR) downgraded to Market Perform from Outperform at Keefe Bruyette... F5 Networks (FFIV) downgraded to Neutral from Buy at Citigroup... F5 Networks (FFIV) downgraded to Neutral from Overweight at Piper Jaffray... Juniper (JNPR) downgraded to Equal Weight from Overweight at Barclays... Kimberly Clark (KMB) downgraded to Underperform from Market Perform at BMO Capital... MFA Financial (MFA) downgraded to Hold from Buy at Jefferies... Mattel (MAT) downgraded to Hold from Buy at KeyBanc... Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo... Vitran (VTNC) downgraded to Hold from Buy at Cowen... Western Asset Mortgage (WMC) downgraded to Hold from Buy at Jefferies... BT Group (BT) downgraded to Equal Weight from Overweight at Morgan Stanley... F5 Networks (FFIV) downgraded to Hold from Buy at Topeka... National American University (NAUH) downgraded to Market Perform at Wells Fargo... Rigel Pharmaceuticals (RIGL) downgraded to Market Perform from Outperform at BMO Capital.
News For COR;EVR;FFIV;JNPR;KMB;MFA;MAT;TEX;WMC;BT;RIGL;NAUH;VTNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 24, 2015
15:46 EDTJNPRJuniper CIO leaving company for same role at VMware, Business Insider says
Subscribe for More Information
15:28 EDTJNPRJuniper to hold an analyst and investor update
Subscribe for More Information
09:02 EDTJNPRJuniper adds 2 directors to board, announces agreement with Elliott
Subscribe for More Information
07:14 EDTJNPRCantor to hold a conference
Subscribe for More Information
February 23, 2015
12:21 EDTRIGLOn The Fly: Midday Wrap
Subscribe for More Information
10:15 EDTFFIVCyberArk sinks after JPMorgan analyst cuts rating to sell
Subscribe for More Information
09:25 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTKMBKimberly Clark signs agreements to purchase pension annuity contracts
Kimberly-Clark announced it has entered into purchase agreements with The Prudential Insurance Company of America and Massachusetts Mutual Life Insurance Company for group annuity contracts that will transfer payment responsibility for retirement pension benefits owed to approximately 21,000 Kimberly-Clark retirees in the U.S. to the two insurers. By transferring the obligations to Prudential and MassMutual, Kimberly-Clark will reduce its pension projected benefit obligation by approximately $2.5B. Kimberly-Clark expects to make a $400M to $475M contribution to its U.S. pension plan to support this transaction. This contribution will be funded by debt financing and is incremental to the company's previous assumption for 2015 global defined benefit pension plan contributions of up to $100M. As a result of the annuity purchases, Kimberly-Clark expects to recognize a non-cash pension settlement charge of $0.8 billion after tax ($1.3 billion before-tax) in the second quarter of 2015. This charge will be excluded from the company's 2015 adjusted results.
08:15 EDTRIGLRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTRIGLBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigelís extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune systemís activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibbís Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigelís TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
February 19, 2015
09:59 EDTTEXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:06 EDTTEXTerex downgraded at BMO Capital
Subscribe for More Information
09:03 EDTKMBKimberly Clark increases dividend 4.8% to 88cc
Subscribe for More Information
06:11 EDTTEXTerex downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
February 18, 2015
16:32 EDTKMBKimberly Clark CFO Buthman plans to retire at year end, Maria Henry to succeed
Subscribe for More Information
07:18 EDTFFIVF5 Networks coverage assumed with an Outperform at Credit Suisse
Subscribe for More Information
February 17, 2015
18:36 EDTTEXOn The Fly: After Hours Movers
Subscribe for More Information
17:31 EDTTEXTerex sees FY15 EPS $2.00-$2.30, consensus $2.60
Subscribe for More Information
17:27 EDTTEXTerex reports Q4 adjusted EPS 72c, consensus 68c
Subscribe for More Information
16:32 EDTTEXTerex increases dividend 20% to 6c
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use